Laibao Wang

Title: Laibao Wang: Innovator in Pharmaceutical Synthesis

Introduction

Laibao Wang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical synthesis, particularly in the development of selective kinase inhibitors. With a total of 2 patents, his work is recognized for its innovative approaches and practical applications in drug development.

Latest Patents

Wang's latest patents include a method for synthesizing furoimidazopyridine compounds. One notable invention is a compound identified as 2-[(2R,5S)-5-[2-methylfuro[3,2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitrile, which serves as a selective JAK1/TYK2 kinase inhibitor. This compound is synthesized using 7-chloro-6-nitrofuro[3,2-b]pyridine as the starting material, employing nucleophilic substitution, palladium on carbon reduction, and cyclization reactions. The synthesis method is characterized by mild reaction conditions, high product yield, and high purity, making it suitable for industrial production. Additionally, he has developed crystal forms of the compound and its salts, which exhibit favorable physical and chemical properties for drug development.

Career Highlights

Throughout his career, Laibao Wang has worked with notable companies in the pharmaceutical industry, including Hangzhou Highlight Pharmaceutical Co., Ltd. and Biohaven Therapeutics Ltd. His expertise in synthesizing complex compounds has positioned him as a valuable asset in the field of drug development.

Collaborations

Wang has collaborated with esteemed colleagues such as Haihui Liu and Congxin Liang. These partnerships have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Laibao Wang's innovative work in synthesizing furoimidazopyridine compounds has made a significant impact on the pharmaceutical industry. His contributions continue to pave the way for advancements in drug development and therapeutic applications.